GLP-1 receptor agonists — the class of medications that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) — are genuinely remarkable drugs. As a psychiatrist in Palm Beach, Florida, I have watched patients lose significant weight, reverse prediabetes, improve their cardiovascular risk, and regain mobility and confidence they had not felt in years. I prescribe them. I believe in them.
But I also believe in honesty. And the honest conversation about GLP-1 medications includes a long list of side effects that the before-and-after photos on social media are not showing you. Some are merely uncomfortable. Some are medically significant. And some are strange in ways that reach deep into your psychology, your pleasure, and your sense of who you are.
This article is that honest conversation.
THE GOOD NEWS FIRST
GLP-1 medications work by mimicking hormones that regulate blood sugar, slow digestion, and — critically — signal the brain that you are full. Tirzepatide also activates GIP receptors, amplifying these effects. The result is reduced appetite, reduced caloric intake, and for most patients, meaningful and sustained weight loss.
The benefits are real: weight reduction, improved insulin sensitivity, lower cardiovascular risk, better sleep quality in many patients, and for some, remission of type 2 diabetes. These are not trivial outcomes. For patients carrying significant metabolic disease, these medications can be life-changing and potentially life-saving.
But the same mechanism that makes them so effective — acting on the brain’s reward and regulatory systems — is also responsible for a constellation of side effects that deserve far more clinical attention than they currently receive.
THE SMELL NOBODY WARNS YOU ABOUT
One of the most surprising and socially distressing side effects of GLP-1 medications is a distinctive change in breath and body odor. Patients describe it as sulfuric — rotten eggs, or something close to it.
This happens for several reasons. The medications slow gastric emptying dramatically, meaning food sits in the digestive tract longer than it normally would. As it ferments, sulfur-containing compounds are produced and released through breath and sweat. Simultaneously, the rapid fat breakdown that accompanies significant weight loss produces ketones, which have their own sharp, acetone-like odor.
The result can be genuinely distressing — not just to the patient but to those around them. It is one of the most underreported side effects in clinical trials and one of the most commonly mentioned in patient communities online. Staying well hydrated, maintaining excellent oral hygiene, and eating smaller, more frequent meals can help, but for many patients it persists as long as they are actively losing weight.
YOUR GUT ON GLP-1s
Gastrointestinal side effects are the most commonly reported and the most commonly cited reason for discontinuing these medications. Nausea affects a majority of patients, particularly in the early weeks and after dose escalations. For many it is manageable. For some it is severe enough to interfere with daily functioning.
Constipation is extremely common — a direct consequence of slowed gastric motility. Some patients go days without a bowel movement. Others experience the opposite: diarrhea, cramping, and unpredictable urgency. Some cycle between the two.
Vomiting, bloating, excessive belching, and a feeling of persistent fullness or pressure in the abdomen are all reported regularly. These symptoms tend to improve over time but never fully resolve for everyone.
For a small number of patients, more serious gastrointestinal complications have been reported, including gastroparesis — a condition in which the stomach essentially stops emptying properly — and in rare cases, intestinal obstruction. Anyone with a history of gastroparesis should discuss these risks carefully with their physician before starting a GLP-1 medication.
MUSCLE LOSS: THE HIDDEN COST OF RAPID WEIGHT LOSS
Here is something that does not make it into the advertisements: when you lose weight rapidly on a GLP-1 medication, you do not lose fat alone. You lose muscle.
Studies have shown that a significant proportion of the weight lost on semaglutide and tirzepatide — in some analyses, up to 40% — comes from lean muscle mass rather than fat. This matters enormously for long-term health. Muscle is metabolically active tissue. It burns calories at rest, supports bone density, protects joints, and is one of the strongest predictors of longevity and functional independence as we age.
Patients on GLP-1 medications who are not actively resistance training and consuming adequate protein are at real risk of emerging from their weight loss journey lighter on the scale but significantly weaker, with slower metabolism and greater vulnerability to injury and future weight regain.
The clinical recommendation is clear: GLP-1 medications should be paired with a structured resistance training program and protein intake of at least 1 gram per pound of target body weight per day. This is not optional. It is essential.
BONE DENSITY: A CONCERN THAT DESERVES MORE ATTENTION
Related to muscle loss is the issue of bone density. Weight-bearing activity and healthy muscle mass are among the primary drivers of bone strength. Rapid weight loss — regardless of the mechanism — is associated with reductions in bone mineral density.
For older patients, for postmenopausal women, and for anyone with a baseline risk for osteoporosis, this is a serious consideration. The long-term skeletal consequences of sustained GLP-1 use are still being studied, but the early signals are enough to warrant monitoring bone density in at-risk patients and ensuring adequate calcium and vitamin D intake throughout treatment.
THE ANXIETY NOBODY EXPECTED
GLP-1 receptors are not confined to the gut and pancreas. They are expressed throughout the brain, including in regions that govern stress response, emotional regulation, and the autonomic nervous system.
A subset of patients on GLP-1 medications develops new or worsening anxiety. This can manifest as a generalized sense of unease, heightened worry, restlessness, or frank panic attacks. For patients who already carry an anxiety diagnosis, the medication can significantly amplify existing symptoms.
The mechanism is not fully understood, but several factors likely contribute. The physical discomfort of nausea, gastrointestinal distress, and rapid heart rate can trigger anxiety responses in susceptible individuals. Rapid caloric restriction produces metabolic shifts that mimic hypoglycemic states, generating the classic physiological signature of anxiety — shakiness, racing heart, a sense of dread. And the same dopaminergic blunting that reduces food cravings may lower the brain’s overall sense of safety and reward.
As a psychiatrist, I take new anxiety symptoms in patients on GLP-1 medications seriously. This is not something to push through without evaluation.
THE SLEEP DISRUPTION PROBLEM
Sleep complaints are increasingly reported among GLP-1 users, though they remain poorly characterized in the clinical literature. Some patients report difficulty falling asleep. Others describe vivid, disturbing dreams. Others wake frequently through the night.
The likely contributors include gastrointestinal discomfort that worsens when lying down, nocturnal hypoglycemia-adjacent states that produce arousal, and the neurological effects of the medication on brain regions involved in sleep regulation.
The irony is significant: poor sleep is itself one of the strongest drivers of weight gain and metabolic dysfunction. Patients who lose sleep on GLP-1 medications may be partially undermining the very goals the medication is meant to achieve. Sleep quality should be actively monitored and addressed throughout treatment.
WHEN NOTHING FEELS FUN ANYMORE
This is the side effect that surprises patients most — and the one I find most clinically fascinating as a psychiatrist.
GLP-1 receptors are densely expressed in the brain’s mesolimbic dopamine system — the reward pathway. This is the circuit that makes food taste good, makes sex feel pleasurable, makes winning at cards exciting, and makes a cold drink on a hot day feel like a small miracle.
When GLP-1 medications blunt this system — which they appear to do — they do not selectively target food cravings. They reduce reward sensitivity broadly.
Patients describe food losing its pleasure long before hunger returns. They describe sex feeling like a mechanical obligation rather than something they desire. They describe hobbies that once absorbed them feeling hollow. Gambling, alcohol, shopping — behaviors driven by dopamine reward — lose their pull. In some respects this sounds like a feature. Addiction medicine researchers are actively studying GLP-1 medications for their potential to treat alcohol use disorder and other addictions, with genuinely promising early results.
But for the average patient who is not struggling with addiction, the blunting of everyday pleasure — the anhedonia — can feel like a quiet erasure of joy. It does not show up on a lab panel. It does not qualify as a diagnosable side effect in most clinical settings. But it is real, it is common, and it deserves to be part of the informed consent conversation.
“I have had patients tell me they lost forty pounds and felt like they should be happier than they have ever been — but instead they felt strangely empty. The scale changed. The joy did not come back with it.” — Mark G. Agresti, MD
LIBIDO AND SEXUAL FUNCTION
Directly related to the reward system blunting is the effect on sex drive. Reduced libido is reported by a meaningful proportion of GLP-1 users, particularly in the early months of treatment.
In men, rapid weight loss can temporarily lower testosterone before metabolic normalization occurs. In women, caloric restriction affects estrogen and progesterone cycling. In both, the dopaminergic blunting described above reduces the motivational component of sexual desire — the wanting, not just the physical capacity.
The good news is that for most patients, libido improves with sustained weight loss over time — better body image, improved hormonal milieu, greater energy, and restored confidence all contribute meaningfully to sexual health. But the early months can be a difficult period, and patients deserve to know this in advance.
THE MUSCLE AND HAIR LOSS NOBODY MENTIONS
Telogen effluvium — diffuse hair shedding — is reported frequently by patients on GLP-1 medications. It is a well-known consequence of rapid weight loss and significant caloric restriction, triggered by the metabolic stress placed on the body. For most patients it is temporary, resolving as weight stabilizes, but it can be alarming and emotionally distressing, particularly for women.
Adequate protein intake, micronutrient sufficiency, and avoiding excessively aggressive caloric restriction can reduce the severity and duration of hair loss during treatment.
SO SHOULD YOU TAKE IT?
Yes — for the right patient, with the right support, and with eyes fully open.
GLP-1 medications represent a genuine advance in the treatment of obesity and metabolic disease. The weight loss they produce is real, the cardiovascular benefits are documented, and for many patients the quality of life improvement is transformative.
But they are not magic. They are powerful pharmacological agents that act on the brain and body in ways we are still fully mapping. They require active co-management: resistance training to protect muscle, adequate protein to preserve lean mass, bone density monitoring for at-risk patients, psychiatric monitoring for anxiety and mood changes, and honest conversations about the reward system effects that no one is putting in the brochure.
Patients deserve that full picture. And they deserve a clinician who will give it to them straight.
If you are considering a GLP-1 medication, currently taking one and experiencing any of the symptoms described in this article, or simply want a comprehensive evaluation of whether this class of medication is appropriate for you, I encourage you to reach out.
Mark G. Agresti, MD
Mark G. Agresti MD LLC
44 Coconut Rd., Palm Beach, FL 33480